Novartis's Sandoz to acquire GlaxoSmithKline antibiotics business unit - Shopping News


MarketWatch — Novartis AG's Sandoz division said Thursday that it has signed an agreement to buy GlaxoSmithKline PLC's cephalosporin antibiotics business.

The division of the Swiss drug maker said it would pay GlaxoSmithKline $350 million at closing as well as milestone payments of up to $150 million, subject to the terms of the transaction, which is expected to close in the second half of 2021.

The acquisition will grant Sandoz global rights to the Zinnat, Zinacef and Fortum brands in more than 100 markets...


Post a Comment